Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 10,501–10,600 of 15,747
Xie, R., Cheong, L. Y., Zhang, D., Wu, K. C. H., Chan, S. C. W., Au, I. C. H., Leung, K. S. M., Wu, J., Chan, T. M., & Yap, D. Y. H. (2026) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2026.152933 · Cited by 3
Computational investigation of peptidomimetics as potential inhibitors of SARS-CoV-2 spike protein
Ibrahim, M. T., & Tao, P. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2116601 · Cited by 4
Funaki, T., Yamada, M., Miyake, K., Ueno, S., Myojin, S., Aiba, H., Matsui, T., Ogimi, C., Kato, H., Miyairi, I., et al. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.02.020 · Cited by 3
Endoscopy After the COVID-19 Pandemic—What Will Be Different?
Lui, R. N.-S., Tang, R. S. Y., & Chiu, P. W. Y. (2022) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-022-00370-5 · Cited by 3
Ling-Hu, T., Simons, L. M., Dean, T. J., Rios-Guzman, E., Caputo, M., Alisoltani, A., Qi, C., Malczynski, M., Blanke, T., Jennings, L. J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101361 · Cited by 2
A Preference-Based Value Assessment of the Fear of COVID-19 Contagion
Poudel, N., & Ngorsuraches, S. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s431148 · Cited by 3
Case mistaken for leukemia after mRNA COVID-19 vaccine administration: A case report
Lee, S. B., Park, C. Y., Park, S.-G., & Lee, H. J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i33.12268 · Cited by 3
Soto‐Pérez‐de‐Celis, E., Arrieta, O. G., Bargalló‐Rocha, E., et al. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.07.005 · Cited by 3
COVID-19 vaccination in adults with inflammatory bowel disease
Lutz, M. K., Lazarus, S. G., & Caldera, F. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231173130 · Cited by 4
Regan, A. K., Arah, O. A., Fell, D. B., & Sullivan, S. G. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad613 · Cited by 3
“Since the roll-out of effective COVID-19 vaccines in December 2020 in the US [32, 33], the US and most other countries now prioritize COVID-19 vaccination during pregnancy.”
BackgroundComunicação em saúde e desinformação sobre COVID-19 em fact-checking de fake News
Lira, A. I. D. O., Pennafort, V. P. D. S., dos Anjos, J. S. F., Barra, I. P., Costa, E. D. O., & de Mendonça, A. E. O. (2022) · Revista de Enfermagem da UFSM · doi:10.5902/2179769271263 · Cited by 6
Aesthetic Surgery Practice Resumption in the United Kingdom During the COVID-19 Pandemic
Joji, N., Patel, N. G., Nugent, N. F., Patel, N., Mair, M. D., Vadodaria, S. J., Waterhouse, N., Ramakrishnan, V., & Sankar, T. K. (2021) · Aesthetic Surgery Journal · doi:10.1093/asj/sjab364 · Cited by 3
Non-coding RNAs: Circular RNAs (circRNAs)
Saw, P. E., & Song, E. (2025) · Springer eBooks · doi:10.1007/978-981-96-3041-7_7 · Cited by 5
ALQahtani, M. F., Asiri, M. A., Alzahrani, S. K., Alshagawi, Z. A., & Alshubaiki, R. (2022) · Arab Journal of Forensic Sciences and Forensic Medicine · doi:10.26735/vlhb3960 · Cited by 3
Breast cancer (BC) and severe COVID-19 (C-19) outcomes: a matched analysis
Sullivan, M. P., Lei, X. J., Giordano, S. H., & Chávez‐MacGregor, M. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07301-1 · Cited by 3
“Vaccination has been effective in preventing infection and progression to severe disease, although efficacy studies are still ongoing for the various vaccines; in particular, examining how they will fare against recent C-19 variants [15].”
Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments
Abdurrahman, L., Fang, X., & Zhang, Y. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666211013121831 · Cited by 4
The seductive allure of technical language and its effect on covid-19 vaccine beliefs and intentions
Silas, J., Jones, A., Weiss‐Cohen, L., & Ayton, P. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.027 · Cited by 4
Development of Corona-virus-disease-19 Vaccines
Hasegawa, H. (2021) · JMA Journal · doi:10.31662/jmaj.2021-0068 · Cited by 4
“They have successfully finished phase III clinical trials with 95% vaccine efficacy (8) and have been approved in many countries.”
BackgroundJefferies, W. A., Choi, K. B., Ribeca, P., Kari, S., Young, J. B., Hui, E., Qi, S. Y., Garrovillas, E., Fan, J., Cho, B. M. Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66252-3 · Cited by 5
Islam, M. A., Alshayban, D., Naqvi, A. A., Maqsood, M. B., Ishaqui, A. A., Kashif, M., Ali, M., & Haseeb, A. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1078023 · Cited by 4
“A number of vaccine candidates have shown efficacy in clinical trials and have been approved for use in public recently (11, 14, 15).”
BackgroundRahman, A. U., Ikram, M. T., Arif, A., Khan, B. D., Azam, K. U., Fida, M. S., Rahim, A. K., Khan, M. S., Mushtaq, M. H., Fida, R., et al. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000606 · Cited by 3
“Consequential side effects, such as anaphylactic shock, could also occur([6,7]).”
Backgroundliu, A., Necela, B. M., Li, Z., Cogen, D., Wieczorek, M. A., Mummareddy, A., Acampora, M., Reynolds, G. A., Advani, P. P., Moreno-Aspitia, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690495 · Cited by 3
Cutaneous reactions after coronavirus disease 2019 vaccination: Summary of 20 Japanese cases
Akatsuka, T., Sakai, Y., Toyama, T., et al. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16335 · Cited by 3
Safety and Immunogenicity of SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901 in People Living with HIVPreprint
Cheng, S., Lien, C.-E., Hsieh, S., Cheng, C., Liu, W.-D., Lo, C.-L., Ko, W., Chen, Y., Huang, C., Chang, H., et al. (2021) · medRxiv · doi:10.1101/2021.12.08.21267439 · Cited by 3
Molecular basis of Ad5-nCoV Vaccine-Induced Immunogenicity
(2024) · doi:10.1101/2024.06.21.600005 · Cited by 3
Mueed, A., Shariq, A., & Ashar, M. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111270 · Cited by 3
Roffo, F., Orlandella, F. M., Luciano, N., Salvatore, G., & Torino, E. (2026) · Bioengineering · doi:10.3390/bioengineering13020209 · Cited by 3
“Their contribution to the delivery is well-known due to the use of modern mRNA COVID-19 vaccines [6,7], while engineering of cells, such as CAR T cells, is spreading fast [8,9].”
Francis, J. A., Wright, L., Oerlemans, S. K., van Wegen, R., & Falconer, R. J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126196 · Cited by 3
Garduño-Orbe, B., Palma-Ramírez, P. S., López‐Ortiz, E., García-Morales, G., Sánchez-Rebolledo, J. M., Emigdio-Loeza, A., Gómez‐García, A., & López-Ortiz, G. (2025) · Infectious Disease Reports · doi:10.3390/idr17040074 · Cited by 4
“Although vaccination has marked a significant advancement in disease prevention, its effectiveness at the population level has shown substantial heterogeneity, often linked to structural inequalities, including limited access to healthcare services [3–6].”
Barbieri, G., Pizzato, M., Gögele, M., Giardiello, D., Weichenberger, C. X., Foco, L., Bottigliengo, D., Bertelli, C., Barin, L., Lundin, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072650 · Cited by 3
Pulmonary Delivery of Messenger RNA (mRNA) Therapeutics for Respiratory Diseases
Qiu, Y., Chow, M. Y. T., & Lam, J. K. W. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_7 · Cited by 4
Chen, S., Wei, W., Huang, F., Wang, J., Li, X., Geng, Z., Gao, F., Dong, T., Wei, P.-F., Yang, X., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2196893 · Cited by 3
“2 KTR patients Europe (1)(2)(3)(4)(5)(6)(7)(8)(9)”
BackgroundInfluentialVaccins à ADN et à ARN: des technologies également utilisées en vaccinologie vétérinaire
Dory, D., & Jestin, A. (2021) · Bulletin de l Académie vétérinaire de France · doi:10.3406/bavf.2021.70927 · Cited by 3
Dai, N., Zhou, T., Tang, W. Y., Mathews, D. H., & Huang, L. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf245 · Cited by 11
Lai, M., Rocca, V. L., Amato, R., Iacono, E., Filipponi, C., Catelli, E., Bogani, L., Fonnesu, R., Lottini, G., Carli, A. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.08.479661 · Cited by 3
Algarate, S., Serrano, L., Bueno, J., Herrero‐Cortina, B., Alvarado, E., González-Barriga, M. T., Ducons, M., Montero‐Marco, J., Arnal, S., Acha, B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310713 · Cited by 4
“Discussion The efficacy of the administration of two doses of vaccine for SARS-CoV-2 in the general population has been proven in terms of prevention of symptomatic infections [3,4] and, in particular, in terms of a decrease in the number of both symptomatic and asymptomatic infections in healthcare workers [5].”
BackgroundLinsenmeyer, K. D., Gupta, K., Madjarov, R., & Charness, M. E. (2021) · medRxiv · doi:10.1101/2021.08.05.21261562 · Cited by 3
“Vaccines have proven highly efficacious in preventing severe disease and death due to a variety of SARS-CoV-2 variants.(1-5) Vaccination also reduces viral load, asymptomatic infection, and viral transmission for many variants.”
Yang, C., Li, E., Guo, X., Xie, W., Wang, Y., Huang, X., Chiu, S., & Wu, X. (2025) · ACS Nano · doi:10.1021/acsnano.4c17269 · Cited by 3
Namiki, T., Komine‐Aizawa, S., Takada, K., Takano, C., Trinh, Q. D., & Hayakawa, S. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.05.002 · Cited by 3
“Several effective vaccines for COVID-19 have been developed, some of which have an efficacy of as much as 95%, and many countries have implemented vaccination programs [1].”
Park, S., Kim, M. K., & Baek, K. (2021) · Korean Journal of Legal Medicine · doi:10.7580/kjlm.2021.45.4.133 · Cited by 3
Crist, R. M., Barenholz, Y., Cern, A., Clark, K. N., Cullis, P. R., Dean, C. A., Desai, N., Ferrari, M., Germain, M., Giacomantonio, C. A., et al. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70020 · Cited by 5
Xu, W., Zhao, J., Luan, F., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7032 · Cited by 3
An mRNA vaccine industry in the making
Savage, N. J. (2021) · Nature · doi:10.1038/d41586-021-02913-9 · Cited by 4
Sun, X., Zhang, L., Chen, G., Yang, F., Ning, X., Qiu, J., Gao, Y., Yang, J., Zhang, W., zhang, Z., et al. (2025) · mBio · doi:10.1128/mbio.03200-25 · Cited by 3
“Moreover, the logistical challenges associated with mRNA vaccine deployment, particularly their stringent cold-chain requirements (e.g., storage at −70°C for BNT162b2), limit accessibility in resource-limited regions where MPXV remains endemic (15, 16).”
Lymphadenopathy in the era of COVID-19 vaccination – an oncological dilemma in diagnostic imaging
Samkowski, J., Sklinda, K., & Walecki, J. M. (2022) · Polish Journal of Radiology · doi:10.5114/pjr.2022.117560 · Cited by 4
“This is most likely because only patient self-reported symptoms of axillary adenopathy were collected [9].”
BackgroundBlistering Papulosquamous Erythema with Arthralgia: A Quiz
Kurosaki, Y., Ishitsuka, Y., Kato, Y., Arase, N., & Fujiomto, M. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.936 · Cited by 3
“widespread blistering papulosquamous erythema with arthralgia, as indicated previously (12).”
BackgroundInfluentialBardawil, S. A., Barthélémy, P., & Ferey, L. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06656 · Cited by 8
Yang, L., Yarovinsky, T. O., Pham, K., Xi, Y., Lu, P., Iwasaki, A., Rose, J. K., & Liu, C. (2025) · npj Vaccines · doi:10.1038/s41541-025-01260-4 · Cited by 4
Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study
Bianchi, F. P., Stefanizzi, P., Germinario, C. A., Migliore, G., Vimercati, L., Martinelli, A., Lobifaro, A., Diella, G., Larocca, A. M. V., Control Room Working Group, et al. (2022) · Vaccines · doi:10.3390/vaccines10030417 · Cited by 5
“In the phase III studies, the vaccine had a 95% efficacy in preventing infection, including severe complications [8].”
BackgroundVagts, C. L., Chang, Y.-S., Ascoli, C., Lee, J. M., Kai, H., Huang, Y., Cherian, R. A., Sarup, N., Warpecha, S. R., Edafetanure-Ibeh, R., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00025-2022 · Cited by 4
Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod
Ciccone, A., Mathey, G., Prunis, C., & Debouverie, M. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.11.003 · Cited by 4
“[3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
BackgroundToward the full potential of mRNA therapeutics
McNamara, J. O., & Giangrande, P. H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.012 · Cited by 3
Clinical Utility of COVID-19 Vaccination in Patients Undergoing Hemodialysis
Oliver, M. J., & Blake, P. G. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04930422 · Cited by 3
SARS-CoV-2 vaccine candidates: A beginning of the end of COVID-19 pandemic- Editorial
Kakulavarapu, S., Boneva, D., & Elkbuli, A. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.01.098 · Cited by 3
Incorporating mRNA therapeutics into biological treatments of hematologic malignancies
Hunia, J., Tomasik, J., Czerwik, N., Pezeshki, P. S., & Nowis, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680071 · Cited by 6
Eventos adversos posteriores a la vacunación contra COVID-19: un estudio de corte transversal
Fuertes-Bucheli, J. F., Madrid-Bonilla, J. U., Rivas, A., Ordóñez-Londoño, E., Ruao-Bolaños, M. F., Chalparpue-Torres, J. J., Bermúdez-Nessim, A. M., Pineda, D. A. R., Silva, S. A., Pacheco, R., et al. (2022) · Revista de Investigación de la Universidad Norbert Wiener · doi:10.37768/unw.rinv.11.02.a0007 · Cited by 6
“En esta población de estudiantes universitarios de Colombia no se reportó ningún caso de miocarditis ni pericarditis, probablemente porque ningún participante de este estudio tenía entre 12 y 17 años, grupo de edad en el que se ha observado un mayor riesgo de estos eventos, o quizás por la baja incidencia de estos EAP…”
BackgroundInfluentialInterim estimates in null models of COVID-19 vaccine effectiveness
Lisewski, A. M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.03.050 · Cited by 3
COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer
King, D. A., Chi, J., Goyal, S. P., & Saif, M. W. (2021) · Archives of Pharmacology and Therapeutics · doi:10.33696/pharmacol.3.020 · Cited by 2
Spike protein-related proteinopathies: A focus on the neurological side of spikeopathies
Posa, A. (2025) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2025.152662 · Cited by 4
Duminuco, A., Bulla, A., Rosso, R., Romeo, M. A., Cambria, D., Spina, E. L., Ximenes, B., Giallongo, C., Tibullo, D., Romano, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13020111 · Cited by 3
“Evidence to date has shown that the effectiveness of the two vaccines in preventing infection by the COVID-19 virus ranges from 94% to 95% [41].”
Boyce, T. G., McClure, D. L., Hanson, K. E., Daley, M. F., DeSilva, M. B., Irving, S. A., Jackson, L. A., Klein, N. P., Lewin, B. J., Williams, J. T. B., et al. (2024) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5863 · Cited by 4
Chen, W., Lin, Y.-P., Cheng, C., Shen, C., Li, C., Wang, Y., Shih, T., Hong, C., Chang, T., & Shen, C. (2022) · Biosensors · doi:10.3390/bios12100891 · Cited by 4
“The advent of vaccines for COVID-19 has been a solution to the spread of the disease [3,4].”
BackgroundDoneddu, P. E., Briani, C., Cocito, D., Manganelli, F., Fabrizi, G. M., Matà, S., Mazzeo, A. T., Fazio, R., Benedetti, L., Luigetti, M., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15811 · Cited by 5
Tene, Y., Levytskyi, K., Adler, A., Halutz, O., Paran, Y., Goldshmidt, H., Itzhaki‐Alfia, A., Halperin, T., Stepansky, S., Ben‐Ami, R., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.412 · Cited by 4
Quan, J., Ma, C., Panaccione, R., Hracs, L., Sharifi, N., Herauf, M., Markovinović, A., Coward, S., Windsor, J. W., Caplan, L., et al. (2022) · medRxiv · doi:10.1101/2022.03.16.22272440 · Cited by 3
Joshi, M. M., Darooka, N., Saha, S., Dyball, S., Sen, P., Yaadav, P., Javaid, M., Kadam, E., Shinjo, S. K., Dey, D. I., et al. (2024) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.15161 · Cited by 5
Black, B. S., & Thaw, D. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4155493 · Cited by 3
COVID-19 Vaccines - Current State and Perspectives
Abdurakhmonov, I. Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101006 · Cited by 7
Schuurmans, M. M., Muszyński, M., Li, X., Marcinkevičs, R., Zimmerli, L., López, D. M., Michel, B., Weiß, J., Hage, R., Roeder, M., et al. (2023) · Medicina · doi:10.3390/medicina59030617 · Cited by 5
“Nevertheless, the proportion of those who reported local and systemic reactions and the type of reactions noted were similar to those observed in larger studies [29,30], particularly those using a similar methodology [12].”
Resultvon Sneidern, M., von Sneidern, M., Saeedi, A., et al. (2024) · Facial Plastic Surgery & Aesthetic Medicine · doi:10.1089/fpsam.2023.0277 · Cited by 3
SARS-CoV-2 mRNA vaccines do not worsen autoimmunity in patients with autoimmune liver diseases
Kälin, T., Passarin, K., Sinnreich, M. F., Semela, D., Seifert, T., Sallusto, F., Vergani, D., Cerny, A., Mieli‐Vergani, G., & Beretta‐Piccoli, B. T. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103325 · Cited by 3
COVID toes following vaccination
Cavazos, A., Deb, A., Sharma, U., & NUGENT, K. M. (2022) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2022.2043732 · Cited by 3
Sáez‐Peñataro, J., Torres, F., Bartra, J., Bascuas, J., Vilella, A., Tortajada, M., Quesada, S., González, E., López‐Suñé, E., Castells, A., et al. (2022) · BioDrugs · doi:10.1007/s40259-022-00543-9 · Cited by 5
“Randomized clinical trials of mRNA-based vaccines reported an overall acceptable safety profile [1, 2].”
BackgroundSymptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses
Caponio, V. C. A., Lipsi, M. R., Fortunato, F., Arena, F., & Muzio, L. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19020886 · Cited by 3
“Their short-term efficacy has been comparable with that of other common vaccines in phase 3 trials and a reduced symptomatic SARS-CoV-2 infection by over 90% was observed in healthy participants, after vaccination [1,2].”
ResultEvidence of quality of life for hospitalised patients with COVID-19: a scoping review
Webb, E., King, N. V., Howdon, D., Carrol, E. D., Euden, J., Howard, P., Pallmann, P., Llewelyn, M., Thomas‐Jones, E., Shinkins, B., et al. (2023) · Health Technology Assessment · doi:10.3310/atpr4281 · Cited by 3
Nešić, A., Stojsavljević, A., Jagodić, J., Cavic, M. R., Stanojević, A., Manojlović, D., & Gavrović-Jankulović, M. Đ. (2022) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2022.127079 · Cited by 3
“Following a SARS-CoV-2 infection, most patients develop detectable specific IgG antibodies to the receptor-binding domain (RBD) of the viral spike glycoprotein and associated neutralizing activities [1, 3, 5, 8, 9].”
BackgroundInfluentialIs the Effect of the COVID-19 Vaccine on Heart Rate Variability Permanent?
Kerkütlüoğlu, M., Güneş, H., İyigün, U., Dağli, M., & Doğaner, A. (2023) · Medicina · doi:10.3390/medicina59050852 · Cited by 4
“Food and Drug Administration to prevent COVID-19 infection was a BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech COVID vaccine), which encoded the spike protein of SARS [2,3].”
BackgroundUpper extremity deep venous thrombosis after BNT162b2 mRNA COVID‐19 vaccine case report
Gonzalez, S. C., & Levine, D. M. (2023) · Clinical Case Reports · doi:10.1002/ccr3.6012 · Cited by 3
Wong, J., Donegan, K. L., Harrison, K., Jan, T., Cave, A. C., & Tregunno, P. (2025) · Drug Safety · doi:10.1007/s40264-025-01579-w · Cited by 4
“…clinical trials with higher reporting of local and systemic events following administration of the Pfizer mRNA vaccine in younger individuals and after a second dose [30] and in younger individuals after a first dose following administration of the AstraZeneca adenoviral vectored vaccine [31].”
Ohmura, S., Yonezawa, H., Yukishima, T., Gohto, Y., & Obana, A. (2024) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxae042 · Cited by 5
COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population
Mayer, D., Barun, B., Lazibat, K., Lasić, S., Adamec, I., Gabelić, T., Skorić, M. K., & Habek, M. (2023) · Acta Neurologica Belgica · doi:10.1007/s13760-023-02296-w · Cited by 3
The microRNA target site profile is a novel biomarker in the immunotherapy response
Bai, Y., Li, Y., Qin, Y., Yang, X., Tseng, G. C., Kim, S., & Park, H. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225221 · Cited by 3
Ashokkumar, C., Rohan, V., Kroemer, A., Rao, S., Mazariegos, G. V., Higgs, B. W., Nadig, S. N., Almeda, J. L., Dhani, H., Khan, K., et al. (2023) · Journal of Surgery and Research · doi:10.26502/jsr.10020321 · Cited by 7
Tong, R., Zhong, J., Li, R., Chen, Y., Hu, L., Li, Z., Shi, J., Lin, G., Lyu, Y., Li, H., et al. (2021) · medRxiv · doi:10.1101/2021.05.06.21256781 · Cited by 3
Ammitzbøll, C. G., Thomsen, M. K., Andersen, J. B., Jensen, J. M. B., Bayarri‐Olmos, R., Garred, P., Hermansen, M. F., Johannsen, A. D., Larsen, M. L., Mistegaard, C. E., et al. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/orpp04 · Cited by 3
Wang, D., Wang, H., Wan, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.13.584850 · Cited by 3
A tumor-selective mRNA system enables precision cancer treatment
Żak, M. M., Yoo, J., Utrero‐Rico, A., Walter, W., Mainkar, G., Adjmi, M., Kurian, A. A., Rahaman, A., Lozano‐Ojalvo, D., Ochando, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.015 · Cited by 6
Evidence of Exhausted Lymphocytes after the Third anti-SARS-CoV-2 Vaccine Dose in Cancer PatientsPreprint
Fuentes, J. D. B., Mohamed, K. M., Aguilar, A. D. L., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1777911/v1 · Cited by 3
Gul, W., Samin, K. A., Ahmad, R. M., Ullah, K., Mehnaz, G., & Ahmed, A. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs211572334 · Cited by 4
Wang, C., & Young, Y. (2023) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2023.103970 · Cited by 3
Hybrid immunity to SARS‐CoV ‐2 in patients with chronic lymphocytic leukemia
Mellinghoff, S. C., Robrecht, S., Sprute, R., Mayer, L., Weskamm, L. M., Dahlke, C., Gruell, H., Teipel, F., Schlößer, H., Siepmann, K., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14170 · Cited by 3
End-to-end SARS-CoV-2 transmission risks in sport: Current evidence and practical recommendations
Jones, B. L., Phillips, G., Valeriani, F., Edwards, T., Adams, E. R., Bonadonna, L., Copeland, R., Cross, M., Dalton, C., Hodgson, L., et al. (2021) · South African Journal of Sports Medicine · doi:10.17159/2078-516x/2021/v33i1a11210 · Cited by 4
del Riego, E. S., Sáiz, M. L., Corte-Iglesias, V., Gordillo, B. L., Martín-Martín, C., Rodríguez-Pérez, M., Escudero, D., López‐Larrea, C., & Suárez-Álvarez, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942192 · Cited by 3
“We know that mRNA vaccines, in particular Pfizer-BioNTech (BNT162b2, Comirnaty) and Moderna (mRNA-1273, Spikevax), provide up to 95% protection against COVID-19 (1, 2), but the level of specific neutralizing antibodies against the S protein diminish over time.”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.